An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer

Cancer Gene Therapy

Volumn 14, Issue 5, 2007, Pages 480-487

  Fu, X ^a,b   Tao, L ^a,b   Zhang, X ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

HSV 2; Metastatic; Oncolytic virus; Ovarian cancer; Ras signaling pathway

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PERITONEAL CAVITY; PERITONEUM TUMOR; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; VIRUS MUTANT;

ANIMALS; FEMALE; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MICE, INBRED STRAINS; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MUS; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 34247140640     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701033     Document Type: Article

References (32)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
3. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
4. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
5. Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000; 7: 275-283.
6. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RCJ et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane-fusion mechanisms. Clin Cancer Res 2003; 9: 2727-2733.
7. Randazzo BP, Kesari S, Gesser RM, Alsop D, Ford JC, Brown SM et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 1995; 211: 94-101.
8. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 1996; 93: 11313-11318.
9. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-3966.
10. Martuza RL. Act locally, think globally. Nat Med 1997; 3: 1323.
11. Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP et al. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 1999; 252: 1-12.
12. Pennisi E. Will a twist of viral fate lead to a new cancer treatment? Science 1996; 274: 342-343.
13. Chung TD, Wymer JP, Smith CC, Kulka M, Aurelian L. Protein kinase activity associated with the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). J Virol 1989; 63: 3389-3398.
14. Smith CC, Nelson J, Aurelian L, Gober M, Goswami BB. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/ MEK/MAPK mitogenic pathway are required for timely onset of virus growth. J Virol 2000; 74: 10417-10429.
15. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001; 3: 745-750.
16. Fu X, Tao L, Cai R, Prigge J, Zhang X. A Mutant Type 2 Herpes Simplex Virus Deleted for the Protein Kinase Domain of the ICP10 Gene Is a Potent Oncolytic Virus. Mol Ther 2006; 13: 882-890.
17. Fu X, Tao L, Jin A, Vile R, Brenner M, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus provides potent synergistic anti-tumor effect. Mol Ther 2003; 7: 748-754.
18. Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors [In Process Citation]. Hum Gene Ther 1998; 9: 2787-2794.
19. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62: 2306-2312.
20. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
21. Schellingerhout D, Bogdanov Jr A, Marecos E, Spear M, Breakefield X, Weissleder R. Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 1998; 9: 1543-1549.
22. Wood M, Perrotte P, Onishi E, Harper ME, Dinney C, Pagliaro L et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 1999; 6: 367-372.
23. Ulbricht A, Farber I, Wutzler P. Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate. Acta Virol 1985; 29: 493-498.
24. Goodman ZD, Ishak KG, Sesterhenn IA. Herpes simplex hepatitis in apparently immunocompetent adults. Am J Clin Pathol 1986; 85: 694-699.
25. Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A, Woo SL. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004; 64: 3265-3270.
26. Su HK, Eberle R, Courtney RJ. Processing of the herpes simplex virus type 2 glycoprotein gG-2 results in secretion of a 34,000-Mr cleavage product. J Virol 1987; 61: 1735-1737.
27. Duerst RJ, Morrison LA. Herpes simplex virus 2 virion host shutoff protein interferes with type I interferon production and responsiveness. Virology 2004; 322: 158-167.
28. Ashkar AA, Rosenthal KL. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol 2003; 77: 10168-10171.
29. Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR. J Immunol 2003; 170: 1430-1434.
30. Ahmad A, Sharif-Askari E, Fawaz L, Menezes J. Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction. J Virol 2000; 74: 7196-7203.
31. Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast Jr RC et al. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 1998; 58: 2253-2259.
32. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.